| Autor: |
Oner Ozgon, G., Langaee, T. Y., Feng, H., Buyru, N., Ulutin, T., Hatemi, A. C., Siva, A., Saip, S., Johnson, J. A. |
| Předmět: |
|
| Zdroj: |
European Journal of Clinical Pharmacology; Sep2008, Vol. 64 Issue 9, p889-894, 6p, 6 Charts, 1 Graph |
| Abstrakt: |
The objective of this study was to determine the quantitative influence of vitamin K epoxide reductase complex subunit 1 ( VKORC1) and cytochrome P450 2C9 ( CYP 2C9) polymorphisms on warfarin dose requirements in Turkish patients. A total of 205 patients taking warfarin for >2 months were enrolled in the study. Deoxyribonucleic acid (DNA) samples from these patients were genotyped for polymorphisms in VKORC1 and CYP2C9 genes. A linear regression analysis was used to determine the independent effects of genetic and non-genetic factors on mean warfarin dose requirements. The VKORC1 promoter polymorphism (3673 G>A) was associated with differences in weekly mean varfarin dose: for GG genotype the dose was 43.18 mg/week, for GA genotype 33.78 mg/week and for AA genoype 25.83 mg/week ( P < 0.0001). Patients who carried VKORC1 and CYP2C9 variants needed a 40% lower mean weekly warfarin dose compared to wild types. Variables associated with lower warfarin dose requirements were VKORC1 3673 AA or GA genotype (both P < 0.0001), one or two CYP2C9 variant alleles (both P < 0.0001), increasing age ( P < 0.0001) and non-indication of venous thromboembolism for warfarin therapy ( P = 0.002). Polymorphisms in VKORC1 and CYP2C9 genes were important determinants of warfarin dose requirements in Turkish patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink